A phase III study of adjuvant chemotherapy in advanced nasopharyngeal carcinoma patients | |
---|---|
學年 | 90 |
學期 | 2 |
出版(發表)日期 | 2002-04-01 |
作品名稱 | A phase III study of adjuvant chemotherapy in advanced nasopharyngeal carcinoma patients |
作品名稱(其他語言) | |
著者 | Chi, Kwan-Hwa; 張玉坤; Chang, Yue-cune; Guo, Wan-Yao; Leung, Mein-Jung; Shiau, Cheng-Yin; Chen, Sheng-Yu |
單位 | 淡江大學數學學系 |
出版者 | Elsevier |
著錄名稱、卷期、頁數 | International Journal of Radiation Oncology, Biology, Physics 52(5), pp.1238-1244 |
摘要 | Full-size image (<1 K) To evaluate the role of adjuvant chemotherapy in locally advanced nasopharyngeal carcinoma (NPC) patients, we conducted a randomized Phase III trial comparing radiotherapy (RT) followed by adjuvant chemotherapy to RT alone in patients with advanced NPC. Full-size image (<1 K) Between November 1994 and March 1999, 157 patients with Stage IV, M0 (UICC/AJCC, 1992) advanced NPC disease were randomized to receive standard radiotherapy, as follows: 35–40 fractions, 1.8–2.0 Gy/fraction/day, 5 days/week, to a total dose 70–72 Gy with or without 9 weekly cycles of 24-h infusional chemotherapy (20 mg/m2 cisplatin, 2,200 mg/m2 5-fluorouracil, and 120 mg/m2 leucovorin) after RT. Of 157 patients enrolled, 154 (77 radiotherapy, 77 combined therapy) were evaluable for survival and toxicity analysis. Full-size image (<1 K) With a median follow-up of 49.5 months, the 5-year overall survival and relapse-free survival rates were 60.5% vs. 54.5% (p = 0.5) and 49.5% vs. 54.4% (p = 0.38) for the radiotherapy-alone group and the combined radiotherapy and adjuvant chemotherapy group, respectively. The Cox regression showed that the hazard rates ratio of combined treatment to RT alone was 0.673 (p value = 0.232); the 95% confidence interval was 0.352 and 1.288, respectively. Patients who received combined treatment had a lower systemic relapse rate than radiotherapy-alone patients, according to relapse pattern analysis. The incidence of leukopenia (≥ Grade 3) occurred in 17 out of 819 (2.1%) cycles of weekly chemotherapy. No patient developed moderate to severe mucositis (≥ Grade 3). Full-size image (<1 K) We conclude that adjuvant chemotherapy after RT for patients with advanced NPC has no benefit for overall survival or relapse-free survival. |
關鍵字 | Nasopharyngeal carcinoma;Adjuvant chemotherapy;Radiotherapy;Chemotherapy |
語言 | en_US |
ISSN | 0360-3016 |
期刊性質 | 國外 |
收錄於 | |
產學合作 | |
通訊作者 | |
審稿制度 | 否 |
國別 | USA |
公開徵稿 | |
出版型式 | ,紙本 |
相關連結 |
機構典藏連結 ( http://tkuir.lib.tku.edu.tw:8080/dspace/handle/987654321/41259 ) |